Showing results (61-70 of 92) with videos related to
Sort By:
Pageof 10
Antisense & Nucleic Acid Drug Development|November 15, 1997
Characterization and modulation of immune stimulation by modified oligonucleotidesR T Boggs, K McGraw, T Condon, et al.Cancer Letters|July 4, 1998
Human melanoma metastasis is inhibited following ex vivo treatment with an antisense oligonucleotide to protein kinase C-alphaJ U Dennis, N M Dean, C F Bennett, et al.Journal of Pharmaceutical Sciences|April 1, 1994
Lipid membrane permeability of 2'-modified derivatives of phosphorothioate oligonucleotidesJ A Hughes, C F Bennett, P D Cook, et al.Trends in Pharmacological Sciences|March 1, 1989
The signal transduction system of the leukotriene D4 receptorS T Crooke, M Mattern, H M Sarau, et al.Anti-Cancer Drug Design|February 1, 1993
Growth inhibition of human tumor cell lines by antisense oligonucleotides designed to inhibit p120 expressionL Perlaky, Y Saijo, R K Busch, et al.The Journal of Biological Chemistry|March 30, 2001
A constitutive cytoprotective pathway protects endothelial cells from lipopolysaccharide-induced apoptosisD D Bannerman, J C Tupper, W A Ricketts, et al.Transplantation Proceedings|December 1, 1995
Efficacy of ICAM-1 antisense oligonucleotide in pancreatic islet transplantationS M Katz, B Browne, T Phan, et al.Neurobiology of Disease|June 20, 2022
Combinatorial ASO-mediated therapy with low dose SMN and the protective modifier Chp1 is not sufficient to ameliorate SMA pathology hallmarksA Muinos-Bühl, R Rombo, E Janzen, et al.The American Journal of Pathology|May 5, 2001
Suppression of vascular endothelial growth factor-mediated endothelial cell protection by survivin targetingM Mesri, M Morales-Ruiz, E J Ackermann, et al.The Journal of Pharmacology and Experimental Therapeutics|February 1, 1997
An ICAM-1 antisense oligonucleotide prevents and reverses dextran sulfate sodium-induced colitis in miceC F Bennett, D Kornbrust, S Henry, et al.Pageof 10